Chimeric antigen receptor modified T‐cells for cancer treatment

Chronic Diseases and Translational Medicine - Tập 4 - Trang 225-243 - 2018
Xiao Han1, Yao Wang1, Wei-Dong Han1
1Molecular & Immunological Department, Bio-therapeutic Department, The General Hospital of People's Liberation Army, Beijing 100853, China

Tóm tắt

AbstractT cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti‐cluster of differentiation (CD)19 CAR‐T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), and a complete remission rate as high as 90% was observed, in both children and adults. Although the achievement of clinical efficacy using CAR‐T cell therapy for solid tumors has encountered several obstacles that were associated with the multiple mechanisms contributing to an immunosuppressive microenvironment, investigators are exploring more optimized approaches to improve the efficiency of CAR‐T in solid tumors. In addition, cytokine release syndrome (CRS) and neurotoxicity following CAR‐T cell therapy can be severe or even fatal; therefore, the management of these toxicities is significant. Herein, we briefly review the structure of CAR‐T and some novel CAR designs, the clinical application of CAR‐T cell therapies, as well as the assessment and management of toxicities.

Tài liệu tham khảo

10.1186/s13045-017-0423-1 10.1073/pnas.86.24.10024 10.1182/blood.V124.21.380.380 10.1186/s40164-017-0070-9 10.18632/oncotarget.5582 10.1126/science.359.6375.598-b 10.1186/s13045-017-0535-7 10.1016/j.clim.2014.10.002 10.1182/blood-2007-12-128843 10.1038/nm.4441 10.1158/1078-0432.CCR-16-1365 10.1038/mt.2014.164 10.1182/blood-2016-04-711903 10.1126/scitranslmed.3008226 10.1056/NEJMoa1407222 10.1172/JCI85309 10.1158/2326-6066.CIR-15-0231 10.1155/2016/3850839 10.1186/s13045-018-0568-6 10.1001/jamaoncol.2017.0184 10.1158/2326-6066.CIR-13-0170 10.1158/1078-0432.CCR-14-1421 10.1126/scitranslmed.aaa4963 10.1182/blood-2017-07-793760 10.1200/jco.2015.33.15_suppl.7010 10.1038/nrclinonc.2017.148 10.1186/s40364-018-0116-0 10.1016/j.canlet.2018.03.010 10.1007/s11899-017-0417-7 10.1158/0008-5472.CAN-14-3321 10.15252/emmm.201607485 10.1016/j.it.2015.06.004 10.1093/jnci/djv439 10.1073/pnas.90.2.720 10.1038/nrclinonc.2016.36 10.1038/leu.2017.57 10.1158/0008-5472.CAN-04-0454 10.1038/mt.2009.83 10.1016/j.ymthe.2005.04.016 10.1089/hum.2009.122 10.1158/2326-6066.CIR-14-0127 10.1016/j.coi.2015.01.002 10.1158/2159-8290.CD-12-0548 10.4049/jimmunol.161.6.2791 10.1038/sj.leu.2403302 10.1172/JCI46110 10.1182/blood.V96.3.785 10.1016/0092-8674(91)90327-U Walker R.E., 2000, Long‐term in vivo survival of receptor‐modified syngeneic T cells in patients with human immunodeficiency virus infection, Blood, 96, 467 10.1016/0006-291X(87)90502-X 10.1016/j.bbmt.2010.03.014 10.1182/blood-2007-12-128843 10.1038/nbt0102-70 10.1038/nrc971 10.1073/pnas.0813101106 10.1097/PPO.0000000000000034 10.1517/14712598.2015.1046430 10.1038/s41598-017-10940-8 10.1158/0008-5472.CAN-11-0103 10.4161/2162402X.2014.994446 10.1182/blood-2011-12-400044 10.1186/s13045-016-0379-6 10.1016/j.cell.2018.03.038 10.1073/pnas.0507496103 10.1182/blood-2011-09-349993 10.1182/blood.V122.21.166.166 10.1172/JCI86721 10.1089/hum.2009.114 10.1016/j.ymthe.2005.07.688 10.1182/blood-2011-04-348540 10.1182/blood-2013-08-519413 10.1097/CJI.0b013e3181ac6138 10.1182/blood-2017-02-769208 10.1126/scitranslmed.3002842 10.1038/nbt.4047 10.1016/j.canlet.2016.07.001 10.1038/nature21405 10.1016/S0140-6736(08)60457-2 10.1038/nrc.2016.97 10.1126/science.1373518 10.3109/10428199509059636 10.1007/s13238-017-0400-z 10.1056/NEJMoa1709919 10.1126/scitranslmed.3005930 10.1097/CCM.0000000000002053 10.1080/2162402X.2015.1027469 10.1158/2159-8290.CD-15-1020 10.1002/cyto.b.20030 10.21037/sci.2016.11.06 10.1182/blood.V128.22.650.650 10.18632/oncotarget.5582 10.1186/s40425-016-0108-2 10.1126/scitranslmed.aac5415 10.1182/blood.V124.21.1982.1982 10.1200/JCO.2015.64.5929 10.1182/blood-2011-10-384388 10.1200/JCO.2014.56.2025 10.1182/blood.V128.22.56.56 10.3324/haematol.2013.085209 10.1038/s41375-018-0075-3 10.1038/nrclinonc.2017.128 10.1182/blood-2007-12-128843 10.1038/sigtrans.2016.2 10.1182/blood-2010-04-281931 10.1056/NEJMoa1708566 10.1172/JCI61245 10.1182/blood-2016-02-699850 Hombach A., 1998, An anti‐CD30 chimeric receptor that mediates CD3‐zeta‐independent T‐cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30, Cancer Res, 58, 1116 10.1097/00002371-199911000-00001 10.1056/NEJMoa1504542 10.1182/blood.V128.22.974.974 10.1200/JCO.2017.35.18_suppl.LBA3001 10.1016/j.jocit.2014.11.001 10.1172/JCI86000 10.1038/nm.4431 10.3389/fimmu.2017.01850 10.1038/nbt.4086 10.2217/imt.14.120 10.1038/mt.2010.24 10.1200/JCO.2014.58.0225 10.1007/s11427-016-5023-8 10.1186/s13045-016-0378-7 O'Rourke D., 2015, IMCT‐15 PILOT study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma, Neuro Oncol, 17, v110 Tanyi J.L., 2015, Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART‐meso) in patients with mesothelin expressing cancers, Cancer Res, 75, CT105, 10.1158/1538-7445.AM2015-CT105 10.1056/NEJMoa1610497 10.1016/S0140-6736(14)61403-3 10.1200/JCO.2016.34.18_suppl.LBA3010 Abbasi J., 2017, Amid FDA approval filings, another CAR‐T therapy patient death, JAMA, 317, 2271, 10.1001/jama.2017.7153 10.1158/2159-8290.CD-17-0698 10.1016/S1470-2045(14)71170-2 10.1158/2159-8290.CD-17-1084
Thông tin
Thông tin xuất bản

Chronic Diseases and Translational Medicine

Tập 4

225-243

Thông tin tác giả